Dec 19, 08
|
| NEW STORY |
| 15:00 ET |
U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
|
|
| NEW STORY |
| 14:19 ET |
Teva and Barr Receive European Commission Approval For Acquisition
|
|
Dec 11, 08
|
| 09:53 ET |
Barr's BLA for Adenovirus Type 4 and 7 Live Oral Vaccines Accepted for Filing by FDA
|
|
Dec 01, 08
|
| 09:06 ET |
FDA Approves Duramed's Synthetic Conjugated Estrogens-A Vaginal Cream
|
|
Nov 26, 08
|
| 12:20 ET |
Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg
|
|
Nov 21, 08
|
| 14:00 ET |
Barr Shareholders Approve Pending Teva Acquisition
|
|
Nov 19, 08
|
| 01:30 ET |
Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent Challenges
|
|
Nov 06, 08
|
| 07:30 ET |
Barr Reports Third Quarter 2008 GAAP Earnings of $0.28 Per Share; Adjusted Earnings of $0.83 Per Share
|
|
Nov 03, 08
|
| 13:41 ET |
Barr Announces Approval of Generic Camptosar(R) Injection, 20 mg/mL
|
|
Oct 27, 08
|
| 17:30 ET |
Teva and Barr Provide Update on Acquisition
|
|
| 09:12 ET |
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
|
|
Oct 24, 08
|
| 12:46 ET |
Barr Confirms Patent Challenge of Oxytrol(R)
|
|
Oct 21, 08
|
| 13:23 ET |
Barr Confirms Patent Challenge of Opana(R) ER Extended-Release Tablets, 5 mg, 10 mg, 20 mg and 40 mg
|
|
Oct 17, 08
|
| 16:03 ET |
Barr Revises Timing of Its Earnings Conference Call to Discuss the Results for the Third Quarter of Calendar 2008 to 9:00 AM Eastern Time
|
|
Oct 16, 08
|
| 11:28 ET |
Barr Says Court of Appeals Upholds 2005 District Court Decision on 1997 Cipro(R) Settlement
|
|
| 10:01 ET |
Barr Announces Date for Special Shareholder Meeting
|
|
Oct 07, 08
|
| 10:06 ET |
Barr Will Host An Earnings Conference Call on November 6, 2008 to Discuss the Results for the Third Quarter of Calendar 2008
|
|
Sep 16, 08
|
| 15:58 ET |
Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
|
|
Sep 03, 08
|
| 14:00 ET |
Teva and Barr Receive FTC Request for Additional Information
|
|
Aug 28, 08
|
| 12:18 ET |
Barr Receives Approval for Generic Version of Razadyne(R) Tablets
|
|
| 08:48 ET |
Barr Announces Favorable Ruling in Razadyne(R) Patent Challenge
|
|
Aug 25, 08
|
| 09:33 ET |
Barr Confirms Patent Challenge of FazaClo(R) Orally Disintegrating Tablets, 25mg and 100mg
|
|
Aug 21, 08
|
| 12:29 ET |
Barr Announces Approval of Generic Pamidronate Disodium Injection, 30mg/10mL, 60mg/10mL and 90mg/10mL
|
|
Aug 20, 08
|
| 08:19 ET |
Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable
|
|
Aug 12, 08
|
| 09:00 ET |
Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges
|
|
Aug 07, 08
|
| 07:25 ET |
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
|
|
Jul 31, 08
|
| 11:57 ET |
Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets
|
|
Jul 29, 08
|
| 09:10 ET |
Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
|
|
Jul 24, 08
|
| 14:45 ET |
Barr Confirms Patent Challenge of Fentora(R) Tablets
|
|
Jul 18, 08
|
| 07:00 ET |
Teva to Acquire Barr
|
|
Jul 03, 08
|
| 10:10 ET |
Barr Will Host an Earnings Conference Call on August 7, 2008 to Discuss the Results for the Second Quarter of Calendar 2008
|
|
Jun 26, 08
|
| 17:20 ET |
Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge
|
|
Jun 24, 08
|
| 02:00 ET |
Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives
|
|
Jun 10, 08
|
| 15:34 ET |
Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
|
|
May 27, 08
|
| 16:04 ET |
Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules
|
|
May 09, 08
|
| 15:35 ET |
Barr Announces Approval of Generic Yasmin(R)
|
|
May 08, 08
|
| 07:26 ET |
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
|
|
Apr 07, 08
|
| 11:26 ET |
Barr Will Host An Earnings Conference Call on May 8, 2008 to Discuss the Results for the First Quarter of Calendar 2008
|
|
Mar 28, 08
|
| 08:58 ET |
Barr Pharmaceuticals, Inc. Executive Bios
|
|
| 08:57 ET |
Barr Announces Reorganization of Senior Management, Business Functions
|
|
Mar 18, 08
|
| 10:00 ET |
Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange
|
|
Mar 12, 08
|
| 15:45 ET |
Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
|
|
Mar 05, 08
|
| 08:57 ET |
Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
|
|
Mar 03, 08
|
| 16:53 ET |
Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
|
|
Feb 28, 08
|
| 07:30 ET |
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
|
|
Feb 26, 08
|
| 08:34 ET |
Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
|
|
Feb 25, 08
|
| 10:06 ET |
Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
|
|
Feb 21, 08
|
| 13:23 ET |
AmniScreen(TM) Amniotic Fluid Detection Device is Now Available
|
|
Feb 19, 08
|
| 12:56 ET |
Barr Receives Final Approval for Generic Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg
|
|
Feb 06, 08
|
| 09:07 ET |
Barr Launches Generic Fosamax(R) Tablets, 70 mg
|
|
Jan 23, 08
|
| 13:43 ET |
SEASONIQUE(R) Patent Issues
|
|
Jan 22, 08
|
| 13:37 ET |
Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
|
|
Jan 18, 08
|
| 12:16 ET |
Barr Will Host Calendar 2007 and Fourth Quarter Earnings Conference Call on February 28, 2008
|
|
Jan 11, 08
|
| 13:02 ET |
Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
|
|
Jan 09, 08
|
| 10:23 ET |
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
|
|
Jan 02, 08
|
| 10:06 ET |
Barr Confirms Patent Challenge of Argatroban(R)
|
|
| 10:04 ET |
Barr Receives Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
|
|
Dec 14, 07
|
| 09:00 ET |
Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
|
|
Nov 29, 07
|
| 14:44 ET |
Barr Receives Approval for Generic Combunox(R) Tablets, 5mg/400mg
|
|
Nov 20, 07
|
| 10:30 ET |
Barr Confirms Patent Challenge of Focalin(R) XR
|
|
Nov 08, 07
|
| 07:27 ET |
Barr Reports Third Quarter 2007 GAAP Earnings of $0.36 Per Share; Adjusted Earnings of $0.75 Per Share
|
|
Nov 02, 07
|
| 11:27 ET |
Barr Confirms Patent Challenge of Ritalin(R) LA
|
|
Oct 30, 07
|
| 09:26 ET |
Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
|
|
Oct 26, 07
|
| 15:59 ET |
Barr's Generic Version of Estrostep(R) Fe Tablets Approved
|
|
Oct 25, 07
|
| 10:52 ET |
Barr Confirms Filing an Application With a Paragraph IV Certification for Patanol(R) Ophthalmic Solution, 0.1%
|
|
Oct 15, 07
|
| 08:30 ET |
Barr and Par Settle Diazepam Rectal Gel Patent Challenge with Valeant
|
|
Oct 05, 07
|
| 09:20 ET |
Barr Will Host Calendar 2007 Third Quarter Earnings Conference Call on November 8, 2007
|
|
Oct 02, 07
|
| 16:13 ET |
Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
|
|
Sep 25, 07
|
| 11:18 ET |
Barr Confirms Patent Challenge of UROXATRAL(R)
|
|
| 08:49 ET |
Patent and Trademark Office Reissues SEASONALE(R) '032 Patent
|
|
Aug 28, 07
|
| 09:06 ET |
Barr's Portia(R) Generic Oral Contraceptive Approved and Launched in Canada
|
|
Aug 15, 07
|
| 12:05 ET |
Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
|
|
Aug 08, 07
|
| 07:15 ET |
Barr Reports Second Quarter 2007 GAAP Earnings of $0.41 Per Share; Adjusted Earnings of $0.84 Per Share
|
|
Aug 02, 07
|
| 07:00 ET |
Barr Announces Departure of President and COO; CEO Downey to Assume Responsibilities
|
|
Jul 24, 07
|
| 09:48 ET |
Barr Confirms Patent Challenge of TEMODAR(R)
|
|
Jul 16, 07
|
| 10:04 ET |
Barr Confirms Patent Challenge of Xopenex(R) Inhalation Solution, 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL
|
|
Jul 12, 07
|
| 12:42 ET |
Barr Confirms Patent Challenge of Aggrenox(R)
|
|
Jul 11, 07
|
| 12:40 ET |
Barr Will Host Calendar 2007 Second Quarter Earnings Conference Call on August 8, 2007
|
|
Jul 09, 07
|
| 09:07 ET |
Barr Announces Approval of Generic Dostinex(R)
|
|
Jul 05, 07
|
| 10:02 ET |
Duramed Announces Canadian Approval of SEASONALE(R) Extended-Cycle Oral Contraceptive
|
|
Jul 02, 07
|
| 14:09 ET |
Barr to Market Generic LAMISIL(R)
|
|
Jun 26, 07
|
| 10:23 ET |
Barr Announces Tentative Approval for a Generic Version of Effexor(R) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg
|
|
Jun 25, 07
|
| 14:05 ET |
U.S. Supreme Court Denies Review of Tamoxifen Citrate Antitrust Lawsuits
|
|
Jun 22, 07
|
| 09:29 ET |
Barr Receives Approval for Generic VESANOID(R) Capsules, 10 mg
|
|
Jun 11, 07
|
| 10:08 ET |
Barr Announces Withdrawal of ZYPREXA(R) Zydis(R) Patent Litigation
|
|
Jun 05, 07
|
| 08:37 ET |
Barr Announces Tentative Approval for a Generic Version of Risperdal(R) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg
|
|
Jun 04, 07
|
| 12:31 ET |
Barr and Eli Lilly Voluntarily Dismiss Patent Litigation on Prozac(R) Weekly(TM)
|
|
Jun 01, 07
|
| 09:15 ET |
Barr Confirms Decision in Azithromycin Inventorship Suit
|
|
May 11, 07
|
| 11:25 ET |
Barr Receives Tentative Approval for a Generic Version of Razadyne(R) Tablets, 4mg, 8mg and 12mg
|
|
May 09, 07
|
| 07:12 ET |
Barr Reports First Quarter 2007 GAAP Earnings of $0.11 Per Share; Adjusted Earnings of $0.78 Per Share
|
|
May 02, 07
|
| 11:31 ET |
Barr Receives Approval for Generic Nimotop(R) Capsules, 30 mg
|
|
Apr 30, 07
|
| 10:30 ET |
Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Tablets Receives Two New FDA Approvals
|
|
Apr 17, 07
|
| 12:49 ET |
Barr Will Host An Earnings Conference Call on May 9, 2007 to Discuss the Results for the First Quarter of Calendar 2007
|
|
Apr 09, 07
|
| 09:42 ET |
Patent and Trademark Office Issues Notice of Allowance on Barr's Reissue Application for SEASONALE(R) '032 Patent
|
|
Apr 06, 07
|
| 11:39 ET |
Barr Confirms Patent Challenge of Ambien CR(R)
|
|
Mar 20, 07
|
| 12:43 ET |
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
|
|
Feb 28, 07
|
| 07:30 ET |
Barr Reports GAAP Loss For Three and Six Months Ended December 31, 2006 of $3.67 Per Share and $3.18 Per Share; Adjusted Earnings For Three and Six Months Were $0.83 Per Share and $1.70 Per Share
|
|
Feb 06, 07
|
| 15:44 ET |
Barr's Subsidiary PLIVA Receives Final Approval for Generic ZOLOFT(R) Tablets, 25 mg, 50 mg and 100 mg
|
|
Jan 30, 07
|
| 14:59 ET |
Barr Launches Generic PROSCAR(R) Tablets, 5 mg
|
|
Jan 23, 07
|
| 15:34 ET |
Barr Confirms Generic Thalomid(R) Suit Filed
|
|
| 09:28 ET |
Barr's Subsidiary PLIVA Receives Approval for Generic ZITHROMAX(R) IV, 500 mg Vial
|
|
Jan 19, 07
|
| 12:33 ET |
Barr Will Host an Earnings Conference Call on February 28, 2007 to Discuss the Results for the Quarter and Six Months Ended December 31, 2006
|
|
| 08:53 ET |
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
|
|
Jan 18, 07
|
| 11:53 ET |
Barr Receives Tentative Approval for Generic KYTRIL(R) Tablets, 1mg (Base)
|
|
Dec 26, 06
|
| 11:48 ET |
Barr Confirms Generic Thalomid(R) Capsule, 50 mg and 100 mg Application
|
|
| 11:19 ET |
Barr's Subsidiary PLIVA Launches Ondansetron 4 mg and 8 mg Orally Disintegrating Tablets
|
|
Dec 13, 06
|
| 12:11 ET |
Barr Confirms Generic Thalomid(R) Capsule Application
|
|
Nov 28, 06
|
| 03:30 ET |
Barr's Subsidiary PLIVA Receives Approval for Pravastatin Tablets 10mg, 20mg, and 40mg and Tentative Approval for 80mg
|
|
Nov 09, 06
|
| 14:45 ET |
Barr Receives Tentative Approval for a Generic Version of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg and 20mg
|
|
Nov 08, 06
|
| 07:14 ET |
Barr Reports GAAP Earnings of $0.49 Per Share for Quarter Ended September 30, 2006; Adjusted Earnings Were $0.78 Per Share
|
|
Nov 06, 06
|
| 08:36 ET |
Barr Launches Plan B(R) OTC/Rx Dual-Label Product; Awarded 3 Years New Product Exclusivity
|
|
Oct 31, 06
|
| 08:40 ET |
PLIVA Announces Changes in Management and Supervisory Boards
|
|
Oct 24, 06
|
| 08:36 ET |
Barr Finalizes Acquisition of PLIVA d.d.
|
|
Oct 20, 06
|
| 12:36 ET |
Barr Says FTC Has Cleared Acquisition of PLIVA d.d.
|
|
| 02:00 ET |
Barr Acquires PLIVA d.d. Following Official Closing of Tender Offer Process
|
|
Oct 12, 06
|
| 07:31 ET |
Barr's Formal Tender Offer Period for PLIVA d.d. Officially Closes
|
|
Oct 10, 06
|
| 10:14 ET |
Barr Will Host Earnings Conference Call on November 8, 2006 to Discuss the Results for the Quarter Ended September 30, 2006
|
|
Sep 28, 06
|
| 08:03 ET |
Barr Cleared to Launch ADDERALL(R) IR
|
|
Sep 27, 06
|
| 08:13 ET |
Barr Launches Generic ACTIQ(R) Cancer Pain Management Product
|
|
Sep 26, 06
|
| 18:21 ET |
Barr Confirms Patent Challenge of Oxandrin(R) Tablets, 2.5 mg and 10 mg
|
|
| 11:17 ET |
Barr Announces Warner Chilcott Waives Exclusive License for OVCON(R) 35
|
|
Sep 18, 06
|
| 10:52 ET |
U.S. Court of Appeals Denies Rehearing Request in Dismissal of Tamoxifen Citrate Antitrust Lawsuits
|
|
Sep 11, 06
|
| 07:48 ET |
Barr's Amended Tender Offer for PLIVA d.d. Approved for Publication by HANFA
|
|
Sep 08, 06
|
| 09:37 ET |
Barr Files an Amended Tender Offer for PLIVA d.d. With HANFA
|
|
Sep 07, 06
|
| 10:00 ET |
Barr Launches a Generic Version of its SEASONALE(R) Extended-Cycle Oral Contraceptive
|
|
Aug 31, 06
|
| 11:25 ET |
Barr Evaluating Actavis Group's Competing Bid for PLIVA d.d.
|
|
Aug 24, 06
|
| 09:00 ET |
FDA Grants OTC Status to Barr's Plan B(R) Emergency Contraceptive
|
|
Aug 18, 06
|
| 02:30 ET |
Barr Initiates Formal Tender Offer for PLIVA d.d.
|
|
Aug 15, 06
|
| 07:18 ET |
Barr Reports GAAP Earnings of $3.12 Per Share for Fiscal 2006 and GAAP Earnings of $0.76 Per Share for Fourth Quarter on Strong Revenue Growth
|
|
Aug 14, 06
|
| 20:45 ET |
Barr and Shire Sign Three Agreements: A Product Acquisition Agreement for ADDERALL(R); A Product Development Agreement; and A Settlement and License Agreement for ADDERALL XR(R)
|
|
Aug 10, 06
|
| 09:25 ET |
Barr Offer for PLIVA d.d. Approved for Publication by HANFA
|
|
Aug 02, 06
|
| 13:19 ET |
Barr Will Host Fourth Quarter and Full Year Fiscal 2006 Earnings Conference Call on August 15, 2006
|
|
Aug 01, 06
|
| 08:41 ET |
Barr Receives Approval for Generic XANAX XR(R) Tablets
|
|
Jul 28, 06
|
| 09:50 ET |
Barr Files Formal Tender Offer for PLIVA d.d. With HANFA
|
|
Jul 24, 06
|
| 03:30 ET |
Barr Prepared to Satisfy FTC Requirements for Potential Acquisition of PLIVA d.d.
|
|
Jul 14, 06
|
| 09:05 ET |
Duramed and Common Sense Sign Agreement to Develop and Market AL-SENSE(R) Amniotic Fluid Detection Device
|
|
Jul 07, 06
|
| 03:30 ET |
Barr Files for FTC, German Regulatory Approval of Proposed PLIVA Acquisition
|
|
Jul 06, 06
|
| 15:04 ET |
Barr Confirms Patent Challenge of Razadyne(R) ER Capsules
|
|
Jul 03, 06
|
| 03:30 ET |
Barr Board Reaffirms Commitment to HANFA Takeover Process
|
|
Jun 30, 06
|
| 03:00 ET |
Barr Increases Offer for PLIVA d.d. to $2.3 Billion in Cash, or HRK 743 Per Share
|
|
Jun 27, 06
|
| 02:32 ET |
Fact Sheet of Barr Pharmaceuticals, Inc. and PLIVA d.d.
|
|
| 02:31 ET |
Barr Will Host Conference Call to Discuss the Bid for PLIVA d.d.
|
|
| 02:30 ET |
Barr Announces Offer of $2.2 Billion for PLIVA d.d.
|
|
Jun 12, 06
|
| 08:02 ET |
Barr Confirms Settlement With Sandoz Regarding Warfarin Sodium
|
|
May 25, 06
|
| 15:26 ET |
FDA Approves Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive Company's Second Proprietary Extended-Cycle OC to be Available in July
|
|
May 12, 06
|
| 13:40 ET |
Barr Receives Approval for Isotretinoin Capsules USP, 30 mg
|
|
| 08:01 ET |
Barr Will Host Conference Call to Discuss the Non-Final Rejection Notice From Patent and Trademark Office on Duramed's Reissue Application for SEASONALE(R)
|
|
| 08:00 ET |
Barr Confirms Non-Final Rejection Notice From Patent and Trademark Office on Duramed's Reissue Application for SEASONALE(R) '032 Patent
|
|
May 11, 06
|
| 10:10 ET |
Barr Challenging Patents Protecting Prozac(R) Weekly(TM)
|
|
May 08, 06
|
| 07:30 ET |
Duramed's ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) Now Available in Pharmacies Nationwide
|
|
May 04, 06
|
| 07:30 ET |
Barr Confirms Patent Challenge of NASACORT(R) AQ Nasal Spray
|
|
| 07:30 ET |
Barr Reports Third Quarter Fiscal 2006 GAAP Earnings of $0.70 Per Share; Adjusted Earnings of $0.75 Per Share
|
|
Apr 06, 06
|
| 15:03 ET |
Barr Will Host Fiscal 2006 Third Quarter Earnings Conference Call on May 4, 2006
|
|
| 08:54 ET |
Barr's Duramed Withdraws NDA for Lo SEASONALE(R) Extended-Cycle Oral Contraceptive
|
|
Mar 17, 06
|
| 08:34 ET |
Barr Confirms that Additional Clinical Data Is Not Required for Approval of Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive
|
|
Feb 15, 06
|
| 13:53 ET |
Federal Court Affirms Barr Summary Judgment in DDAVP(R) Patent Challenge
|
|
Feb 07, 06
|
| 07:32 ET |
Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per Share; Adjusted Earnings of $0.85 Per Share
|
|
Feb 01, 06
|
| 19:33 ET |
Barr Announces Agreements with Cephalon, Inc. Regarding Settlement of ACTIQ(R) and PROVIGIL(R) Patent Litigations
|
|
Jan 27, 06
|
| 15:12 ET |
Barr Says Court Denies Preliminary Injunction to Halt Generic Allegra(R) Sales
|
|
Jan 20, 06
|
| 11:23 ET |
Barr Will Host Fiscal 2006 Second Quarter Earnings Conference Call on February 7, 2006
|
|
Jan 17, 06
|
| 08:49 ET |
Barr's Duramed Pharmaceuticals Named Title Sponsor of the FUTURES(R) Golf Tour
|
|
Jan 10, 06
|
| 12:18 ET |
Barr Names G. Frederick Wilkinson President and COO of Duramed Pharmaceuticals, Inc.
|
|
Dec 23, 05
|
| 09:00 ET |
Barr Receives Approval for Zonisamide Capsules, 25 mg, 50 mg & 100 mg
|
|
Dec 19, 05
|
| 12:15 ET |
Barr Pharmaceuticals Announces Management Change
|
|
Dec 13, 05
|
| 17:31 ET |
Barr's Downey Files to Exercise Options for Common Shares
|
|
Dec 02, 05
|
| 02:30 ET |
Barr, Organon and Savient Finalize Mircette(R) Settlement and Acquisition
|
|
Nov 10, 05
|
| 08:26 ET |
Duramed Completes Acquisition of FEI Women's Health and ParaGard(R) IUD Product
|
|
Nov 07, 05
|
| 18:04 ET |
Barr Confirms FTC Lawsuit Related to Generic Ovcon-35(R) License
|
|
Nov 03, 05
|
| 14:00 ET |
U.S. Court of Appeals Affirms Dismissal of Tamoxifen Antitrust Lawsuits
|
|
| 12:47 ET |
Barr Announces Extension of Stock Repurchase Program
|
|
Nov 01, 05
|
| 07:33 ET |
Barr Reports First Quarter Fiscal 2006 Earnings of $0.78 Per Share
|
|
Oct 26, 05
|
| 16:48 ET |
Duramed and Paladin Sign SEASONALE(R) Product Canadian License and Distribution Agreement
|
|
Oct 25, 05
|
| 11:39 ET |
Barr Will Host Fiscal 2006 First Quarter Earnings Conference Call on November 1, 2005
|
|
Oct 18, 05
|
| 07:31 ET |
Barr Will Host Conference Call to Discuss Duramed's Acquisition of FEI Women's Health and Its ParaGard(R) IUD Product
|
|
| 07:31 ET |
Duramed to Acquire FEI Women's Health and Its ParaGard(R) IUD Product
|
|
Oct 17, 05
|
| 09:16 ET |
Barr Confirms Patent Challenge of Risperdal(R) M-Tab(R)
|
|
Sep 28, 05
|
| 08:30 ET |
Barr Confirms Patent Challenge of Mirapex(R)
|
|
Sep 21, 05
|
| 11:07 ET |
Barr Confirms That Aventis and Albany Molecular Research, Inc. Are Seeking a Preliminary Injunction on Allegra(R) Tablets
|
|
Sep 14, 05
|
| 08:35 ET |
Barr Receives Approval for Leflunomide Tablets, 10 mg & 20 mg
|
|
Sep 08, 05
|
| 07:32 ET |
Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and GAAP Earnings of $0.40 Per Share for Fourth Quarter
|
|
| 07:32 ET |
Barr, Organon and Savient Announce Letter of Intent Regarding Mircette(R)
|
|
Sep 06, 05
|
| 08:06 ET |
Teva and Barr Announce Launch of Generic Allegra(R) Tablets by Teva Under Agreement With Barr
|
|
Sep 01, 05
|
| 08:27 ET |
Barr Receives Approval for Allegra(R) Tablets
|
|
Aug 26, 05
|
| 16:00 ET |
FDA Defers Decision on Plan B Over-the-Counter Application
|
|
Aug 18, 05
|
| 08:53 ET |
Barr Receives Approvable Letter for Duramed's SEASONIQUE(TM) Extended-Cycle Oral Contraceptive
|
|
Aug 15, 05
|
| 09:41 ET |
Barr Will Host Fiscal 2005 Fourth Quarter and Full Year Earnings Conference Call on September 8, 2005
|
|
Aug 11, 05
|
| 08:35 ET |
Barr Receives Approval for Clonazepam Orally Disintegrating Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg & 2 mg
|
|
Jul 14, 05
|
| 09:13 ET |
Barr Receives Approval For Allegra(R) Capsules
|
|
Jul 05, 05
|
| 08:58 ET |
Barr Receives Approval for DDAVP(R) Tablets, 0.1 mg & 0.2 mg
|
|
Jun 17, 05
|
| 11:40 ET |
Barr Applauds New Hampshire Law Making Emergency Contraception More Accessible
|
|
Jun 15, 05
|
| 10:10 ET |
Barr Confirms Patent Challenge of Razadyne(R) Tablets
|
|
May 25, 05
|
| 08:25 ET |
Barr's Generic Demulen 1/35-28 Oral Contraceptive Tablets Approved
|
|
May 05, 05
|
| 07:30 ET |
Barr Reports Third Quarter Fiscal 2005 Earnings of $0.58 Per Share
|
|
Apr 27, 05
|
| 08:36 ET |
Barr Receives Final FDA Approval for Generic Niaspan(R) Extended-Release Tablets
|
|
Apr 26, 05
|
| 10:57 ET |
Barr's Receives Not Approvable Letter for Bijuva(TM) Vaginal Cream
|
|
Apr 20, 05
|
| 14:16 ET |
Plan B(R) Emergency Contraceptive Granted Non-Prescription Status in Canada
|
|
Apr 18, 05
|
| 14:40 ET |
Barr Will Host Fiscal 2005 Third Quarter Earnings Conference Call on May 5, 2005
|
|
| 13:02 ET |
Barr Receives Approval for Anagrelide Hydrochloride Capsules, 0.5 mg and 1 mg
|
|
Apr 14, 05
|
| 13:23 ET |
Barr Granted Final Approval for Generic Version of Allegra-D(R) 12 Hour Extended-Release Tablets
|
|
Apr 13, 05
|
| 07:31 ET |
Barr Will Host Conference Call to Discuss Agreements Related to Resolution of Patent Litigation Involving Kos' Niaspan(R) Products
|
|
| 07:31 ET |
Kos and Barr Announce Definitive Co-Promotion, Manufacturing, and Settlement Agreements
|
|
Apr 11, 05
|
| 12:27 ET |
Barr Eligible for Sole Exclusivity on Allegra-D(R) 12 Hour
|
|
Apr 01, 05
|
| 10:30 ET |
Barr Granted Summary Judgment on Additional Patent in Allegra(R) Patent Challenge
|
|
Mar 31, 05
|
| 17:05 ET |
Barr Says Court Rejects Ciprofloxacin Antitrust Class Action Suits
|
|
Mar 30, 05
|
| 11:36 ET |
Barr and PLIVA Sign Agreement to Develop and Market Generic Version of G-CSF in United States and Canada
|
|
| 08:31 ET |
Barr and Kos in Settlement Discussions Regarding Niaspan(R) Patent Litigation
|
|
Mar 29, 05
|
| 13:14 ET |
Barr Confirms Filing an Application With a Paragraph IV Certification for Yasmin(R)
|
|
Mar 09, 05
|
| 16:04 ET |
Barr Confirms Kos Is Seeking Court Order to Block Potential Launch of Generic Niaspan(R)
|
|
Feb 09, 05
|
| 09:19 ET |
Court Grants Barr Summary Judgment in DDAVP(R) Patent Challenge
|
|
Feb 04, 05
|
| 09:07 ET |
Barr Sues FDA to Obtain Sole Exclusivity on Allegra-D(R)
|
|
Feb 02, 05
|
| 07:30 ET |
Barr Reports Second Quarter Fiscal 2005 Earnings of $0.56 Per Share
|
|
Jan 25, 05
|
| 07:59 ET |
Barr Confirms Court of Appeals Decision Regarding Natural Biologics Conjugated Estrogen Raw Material
|
|
Jan 21, 05
|
| 18:01 ET |
FDA Decision on Plan B(R) OTC Status Delayed
|
|
Jan 14, 05
|
| 09:15 ET |
Barr Will Host Fiscal 2005 Second Quarter Earnings Conference Call on February 2, 2005
|
|
Jan 07, 05
|
| 12:30 ET |
Barr Receives Tentative Approval for Mirtazapine Orally Disintegrating Tablets, 45 mg
|
|
Dec 28, 04
|
| 08:39 ET |
Barr's Duramed Acquires Exclusive Rights to Nordette(R)
|
|
Dec 22, 04
|
| 08:38 ET |
Duramed's SEASONIQUE(TM) NDA Accepted for Filing by FDA
|
|
Dec 21, 04
|
| 08:03 ET |
Barr Receives FDA Approval for Enjuvia(TM) (Synthetic Conjugated Estrogens, B) 0.3 and 0.45 Mg Tablets
|
|
Dec 13, 04
|
| 15:15 ET |
Barr Receives Approval for Demeclocycline Hydrochloride Tablets USP, 150 mg & 300 mg
|
|
Dec 03, 04
|
| 12:01 ET |
Barr's Generic Version of Videx(R) EC Antiretroviral Agent Approved by FDA
|
|
Dec 02, 04
|
| 14:01 ET |
Barr Confirms Suit Initiating ZYPREXA(R) Zydis(R) Patent Challenge
|
|
Nov 22, 04
|
| 16:20 ET |
Barr's Duramed to Acquire Exclusive Rights to Prefest(R)
|
|
Nov 04, 04
|
| 07:04 ET |
Barr Reports First Quarter Fiscal 2005 Earnings of $0.49 Per Share
|
|
Oct 21, 04
|
| 10:39 ET |
Barr Completes Sales Force Integration
|
|
Oct 20, 04
|
| 09:14 ET |
Barr Will Host Fiscal 2005 First Quarter Earnings Conference Call on November 4, 2004
|
|
Oct 19, 04
|
| 16:08 ET |
Federal Appeals Court Reverses Summary Judgment Decision in Antitrust Litigation
|
|
Oct 18, 04
|
| 08:49 ET |
Barr Receives Approval for Generic Glucophage(R) XR Extended-Release Tablets, 750 mg
|
|
Oct 06, 04
|
| 09:43 ET |
Barr Receives Tentative Approval for Generic Version of Femhrt(R) Tablets
|
|
Sep 30, 04
|
| 08:24 ET |
Barr's Generic Tri-Norinyl(R)-28 Oral Contraceptive Tablets Approved
|
|
Sep 07, 04
|
| 09:24 ET |
Barr Exercises Royalty Option on SEASONALE(R) Extended-cycle Oral Contraceptive
|
|
Aug 31, 04
|
| 10:24 ET |
Barr Obtains $175 Million Credit Facility
|
|
Aug 27, 04
|
| 08:22 ET |
Barr Receives Tentative Approval for a Generic Version of Zofran ODT(R) Orally Disintegrating Tablets
|
|
Aug 10, 04
|
| 07:54 ET |
Barr Granted Rights to Generic of Cephalon's ACTIQ(R) Cancer Pain Treatments
|
|
Aug 05, 04
|
| 07:50 ET |
Barr Announces Stock Repurchase Program
|
|
| 07:48 ET |
Barr Reports Fiscal 2004 GAAP Earnings of $1.15 Per Share and Fourth Quarter GAAP Earnings of $0.13 Per Share
|
|
Jul 22, 04
|
| 11:28 ET |
Barr Submits Response to FDA in Support of Over-the-Counter Status for Plan B(R) Emergency Contraceptive
|
|
| 09:16 ET |
Barr Will Host Fiscal 2004 Fourth Quarter and Full Year Earnings Conference Call on August 5, 2004
|
|
Jul 19, 04
|
| 14:57 ET |
Eastern Virginia Medical School Submits Patent Covering SEASONALE(R) for Reissue With Patent and Trademark Office
|
|
Jul 02, 04
|
| 08:19 ET |
Barr Receives Tentative Approval for Allegra(R)-D Extended-Release Tablets
|
|
Jul 01, 04
|
| 08:44 ET |
Barr Granted Summary Judgment on Three Patents in Allegra(R) Patent Challenge
|
|
Jun 17, 04
|
| 08:32 ET |
Arbitration Panel Rules Against Barr in Contract Dispute With Solvay; Panel Divided Over Damage Award
|
|
May 11, 04
|
| 08:17 ET |
Barr Receives FDA Approval for Enjuvia(TM) (Synthetic Conjugated Estrogens, B)
|
|
May 06, 04
|
| 18:58 ET |
Barr Receives Not Approvable Letter for Over-the-Counter Emergency Contraceptive
|
|
Apr 28, 04
|
| 07:42 ET |
Barr Reports Third Quarter Fiscal 2004 Earnings of $0.33 Per Share Driven by 87% Increase in Revenue
|
|
Apr 27, 04
|
| 16:47 ET |
Barr Announces Agreement with Galen Resolving Outstanding Patent Challenges on Estrostep(R) and femhrt(R)
|
|
Apr 23, 04
|
| 08:30 ET |
Barr's Generic Ovcon-35(R) Tablets Approved
|
|
Apr 14, 04
|
| 08:42 ET |
Barr Will Host Third Quarter Fiscal 2004 Earnings Conference Call on April 28, 2004
|
|
Apr 05, 04
|
| 08:00 ET |
Barr Acquires Rights to Urinary Incontinence Transvaginal Ring Product From Schering AG, Germany
|
|
Mar 25, 04
|
| 02:00 ET |
Barr and Galen Announce Agreements for Duramed to Acquire Exclusive Rights to Galen's Loestrin(R) Oral Contraceptive Products
|
|
Mar 16, 04
|
| 08:05 ET |
Barr Pharmaceuticals Board Announces Stock Split Distribution
|
|
Mar 08, 04
|
| 08:00 ET |
Webcast Alert: Barr Pharmaceuticals, Inc. Will Webcast its Third Annual Analyst Briefing on March 10, 2004
|
|
Mar 01, 04
|
| 08:06 ET |
Webcast Alert: Barr Pharmaceuticals, Inc. Will Webcast its Third Annual Analyst Briefing on March 10, 2004
|
|
Feb 26, 04
|
| 09:34 ET |
Barr Completes Acquisition of Women's Capital Corporation and Plan B(R) Emergency Contraceptive
|
|
Feb 25, 04
|
| 13:02 ET |
Barr Receives Approval for Cyclessa Oral Contraceptive Tablets
|
|
Feb 20, 04
|
| 12:40 ET |
Barr's Downey Exercises Options for Common Shares
|
|
Feb 13, 04
|
| 15:31 ET |
Barr Says FDA Extends Plan B Emergency Contraceptive PDUFA Date
|
|
| 08:45 ET |
Barr Pharmaceuticals Board Announces 3-for-2 Stock Split; Fifth Stock Split in Eight Years
|
|
Feb 06, 04
|
| 08:48 ET |
Barr's Cenestin(R) 0.45 mg Tablets Approved
|
|
Feb 05, 04
|
| 07:27 ET |
Barr's Second Quarter Fiscal 2004 GAAP Earnings of $0.49 Per Share Driven by 79% Increase in Revenues
|
|
Jan 26, 04
|
| 13:11 ET |
Barr Will Host Second Quarter Fiscal 2004 Earnings Conference Call on February 5, 2004
|
|
Jan 09, 04
|
| 10:55 ET |
Barr's Tentative Approval for Metformin XR Withdrawn by FDA
|
|
Jan 08, 04
|
| 10:43 ET |
Barr Receives Tentative Approval for Modafinil Tablets, 100 mg and 200 mg
|
|
Jan 06, 04
|
| 12:52 ET |
Barr Receives Tentative Approval for Topiramate Tablets, 25 mg, 100 mg and 200 mg
|
|
Jan 02, 04
|
| 10:00 ET |
Barr Changes State of Incorporation to Delaware
|
|
Dec 30, 03
|
| 09:28 ET |
Barr Receives Approval for Mefloquine Hydrochloride Tablets
|
|
Dec 29, 03
|
| 13:48 ET |
Barr Launches Generic Version of Ortho Tri-Cyclen(R) Tablets
|
|
Dec 23, 03
|
| 11:45 ET |
Barr and Galen Receive FTC Request for Information Related to Proposed Transactions
|
|
Dec 19, 03
|
| 09:24 ET |
Barr Receives Tentative Approval for Topiramate Capsules, 15 mg and 25 mg
|
|
Dec 18, 03
|
| 09:06 ET |
Barr Receives Approval for and Launches Mirtazapine Orally Disintegrating Tablets, 15mg and 30mg
|
|
Dec 16, 03
|
| 17:52 ET |
FDA Advisory Committees Vote to Allow Over-the-Counter Sale of Emergency Contraceptive
|
|
Dec 04, 03
|
| 10:29 ET |
Barr Announces Challenge of Patents Protecting Prefest(R)
|
|
Dec 03, 03
|
| 07:42 ET |
Barr Will Host Conference Call to Discuss Asset Purchase Agreement with Endeavor Pharmaceuticals, Inc.
|
|
| 07:41 ET |
Barr to Acquire Assets of Endeavor Pharmaceuticals, Inc.; $35 Million Asset Purchase Agreement Signed
|
|
Nov 18, 03
|
| 10:30 ET |
Barr Begins Detailing SEASONALE(R) to Physicians and Healthcare Providers
|
|
Nov 06, 03
|
| 07:34 ET |
Barr Laboratories, Inc. Reports 41% Increase in Revenue Drives First Quarter Fiscal 2004 GAAP Earnings of $0.55 Per Share
|
|
Oct 31, 03
|
| 12:52 ET |
Barr Receives Tentative Approval for Metformin Hydrochloride Extended-Release Tablets, 500 mg
|
|
Oct 30, 03
|
| 08:05 ET |
Barr and Shire Announce Dismissal of ADDERALL(R) Trade Dress Suit
|
|
Oct 23, 03
|
| 11:20 ET |
SEASONALE(R), First and Only Extended-Cycle Oral Contraceptive, Is Now Available in Pharmacies Nationwide
|
|
Oct 21, 03
|
| 17:52 ET |
Barr Will Host First Quarter Fiscal 2004 Earnings Conference Call on November 6th
|
|
Oct 15, 03
|
| 08:05 ET |
Webcast Alert: Barr Laboratories, Inc. Invites You to Join Its 2003 Annual Meeting of Shareholders on the Web
|
|
Oct 09, 03
|
| 09:03 ET |
Barr's Receives Approval for Pyridostigmine Bromide Tablets USP, 60 mg
|
|
Oct 06, 03
|
| 08:26 ET |
Barr Initiates Challenge of Patent Protecting Ortho Tri-Cyclen(R) Lo
|
|
Oct 02, 03
|
| 09:08 ET |
Barr Signs Letter of Intent to Acquire Plan B Emergency Contraceptive
|
|
Sep 25, 03
|
| 08:34 ET |
Barr Signs Amended Agreement to Extend Distribution of Ciprofloxacin
|
|
Sep 18, 03
|
| 12:16 ET |
Barr's Generic Loestrin(R) Fe 1/20 and 1.5/30 Tablets Approved
|
|
Sep 15, 03
|
| 16:37 ET |
Barr to Review Options Following District Court Ruling on Natural Biologics' Generic Premarin(R) Raw Material
|
|
Sep 11, 03
|
| 02:05 ET |
Barr Will Host Conference Call to Discuss Letter of Intent With Galen
|
|
| 02:00 ET |
Barr and Galen Sign Letters of Intent for Barr to Acquire Exclusive Rights to Galen's Loestrin(R) Oral Contraceptive Product
|
|
Sep 05, 03
|
| 17:05 ET |
Barr Will Host a Conference Call to Discuss the Approval of SEASONALE(R), An Extended-Cycle Oral Contraceptive
|
|
| 17:00 ET |
FDA Approves Barr's SEASONALE(R), an Extended-Cycle Oral Contraceptive First and Only Extended-Cycle OC Gives Women New Choice - Four Periods a Year
|
|
Sep 03, 03
|
| 12:04 ET |
Barr Confirms Additional Suit by Shire for Adderall XR(R)
|
|
Aug 21, 03
|
| 15:56 ET |
Barr's Receives Approval for Lithium Carbonate Extended-Release Tablets USP, 450 mg
|
|
Aug 07, 03
|
| 07:51 ET |
Barr Reports Fiscal 2003 GAAP Earnings of $2.43 Per Share and Fourth Quarter GAAP Earnings of $0.53 Per Share
|
|
Jul 31, 03
|
| 16:08 ET |
Barr Will Host Fourth Quarter and Fiscal 2003 Full Year Earnings Conference Call on August 7th
|
|
| 08:33 ET |
Barr Laboratories Announces Agreement in Ortho Tri-Cyclen(R) Patent Litigation
|
|
Jul 09, 03
|
| 18:07 ET |
Barr Announces Voluntary Recall of 3 Lots of Nortrel(TM) 7/7/7 - 28 Day
|
|
Jul 03, 03
|
| 14:57 ET |
Barr Dedicates Adenovirus Manufacturing Facility
|
|
Jun 30, 03
|
| 11:01 ET |
Barr Files Application for an 'AB' Rated Conjugated Estrogens Product
|
|
| 07:01 ET |
Barr Relocates Administrative Headquarters to Bergen County, NJ
|
|
Jun 23, 03
|
| 09:16 ET |
Barr Receives Approval for Extended Phenytoin Sodium Capsules USP, 100 mg
|
|
Jun 16, 03
|
| 14:45 ET |
Barr Receives Tentative Approval for Generic Niaspan(R) 500 mg and 750 mg Extended-Release Tablets
|
|
Jun 10, 03
|
| 12:05 ET |
Barr Completes Agreements to Acquire Wyeth Products; Barr Receives License to Develop, Market Trimegestone Progestin
|
|
Jun 09, 03
|
| 08:55 ET |
Barr Announces Launch of Ciprofloxacin Products
|
|
Jun 03, 03
|
| 09:36 ET |
Barr Receives Not Approvable Letter for Cenestin(R) 0.45 mg Tablets
|
|
Jun 02, 03
|
| 08:28 ET |
Barr's Generic Loestrin(R) 21 1/20 and 1.5/30 Tablets Approved
|
|
May 27, 03
|
| 10:17 ET |
Barr Says Appeals Court Rejects Shire's Request for Preliminary Injunction In Adderall(R) Trade Dress Suit
|
|
May 23, 03
|
| 09:03 ET |
Barr Says FDA Extends PDUFA Deadline for SEASONALE(R) Extended-Cycle(TM) Oral Contraceptive Application
|
|
May 21, 03
|
| 08:10 ET |
Barr Announces Decision in Ciprofloxacin Antitrust Class Action Suits; Ruling Significantly Narrows Focus of Litigation
|
|
May 15, 03
|
| 15:46 ET |
Barr Announces Dismissal of Tamoxifen Antitrust Lawsuits
|
|
May 12, 03
|
| 13:13 ET |
Barr Receives Tentative Approval for Generic Niaspan(R) 1000 mg Extended-Release Tablets
|
|
May 09, 03
|
| 13:33 ET |
Barr Launches Generic Accutane(R) Capsules Product
|
|
Apr 24, 03
|
| 07:48 ET |
Barr Reports Third Quarter 2003 EPS of $0.66
|
|
Apr 15, 03
|
| 13:11 ET |
Barr Will Host Third Quarter Earnings Conference Call on April 24th
|
|
Apr 11, 03
|
| 13:35 ET |
Barr Receives Approval for Generic Accutane(R) Capsules
|
|
Apr 01, 03
|
| 16:48 ET |
Barr to Continue Marketing Kariva(TM) Despite Court of Appeals Decision; Barr's Patent Challenge For Mircette(R) Oral Contraceptive Remanded To District Court for Trial
|
|
Mar 31, 03
|
| 09:44 ET |
Barr Initiates Patent Challenge of Provigil(R) Tablets
|
|
Mar 19, 03
|
| 15:45 ET |
Barr Receives Approval for Generic ADDERALL(R) Tablets, 7.5 mg, 12.5 mg, 15 mg
|
|
Mar 18, 03
|
| 08:54 ET |
Barr Laboratories Board Announces Stock Split Distribution
|
|
Feb 25, 03
|
| 11:42 ET |
Barr Confirms Shire Suit Initiating Adderall XR(TM) Patent Challenge
|
|
Feb 21, 03
|
| 08:49 ET |
Barr Receives Approval for Generic Nolvadex(R) 10 mg and 20 mg Tablets
|
|
Feb 18, 03
|
| 16:31 ET |
Barr Laboratories Board Announces 3 for 2 Stock Split; Fourth Stock Split in Seven Years
|
|
| 09:55 ET |
Barr's CEO Downey to Begin Outpatient Therapy; Returns Home, Resumes Full-Time Business Schedule
|
|
Feb 13, 03
|
| 09:16 ET |
Barr to Relocate Executive Offices to Bergen County, NJ; Signs 12 Year Lease on Woodcliff Lake Facility; Adequate Room for Growth
|
|
Jan 23, 03
|
| 09:08 ET |
Barr Receives Approval for Generic Florinef(R) Acetate Tablets USP, 0.1 mg
|
|
Jan 22, 03
|
| 16:21 ET |
Barr Hosts Second Annual Analyst Meeting
|
|
Jan 21, 03
|
| 08:40 ET |
Barr Reports Second Quarter 2003 EPS of $0.94 - Strong Oral Contraceptive Sales Drive Results -
|
|
Jan 14, 03
|
| 07:50 ET |
Barr Increases Second Quarter Earnings Estimates
|
|
Jan 06, 03
|
| 08:06 ET |
Barr's CEO Downey Undergoing Treatment for Transverse Myelitis; Remains Active in Company Management
|
|
Dec 18, 02
|
| 19:28 ET |
Barr's Generic Ortho Tri-Cyclen(R) Receives Final FDA Approval
|
|
| 19:28 ET |
District Court Refuses to Allow Barr to Market its Manufactured Tamoxifen 10 mg Tablet Before February 2003
|
|
Dec 17, 02
|
| 11:56 ET |
Barr Initiates Patent Challenge of DDAVP(R) Tablets
|
|
Dec 02, 02
|
| 08:08 ET |
Barr Signs Letter of Intent to Acquire Currently Marketed Wyeth Products
|
|
Nov 12, 02
|
| 16:25 ET |
Barr Confirms Evista(R) Patent Challenge
|
|
Nov 07, 02
|
| 07:42 ET |
Barr Reports $0.92 EPS in First Quarter 2003; Strong Sales, Increased Margins Drive Results
|
|
Oct 30, 02
|
| 09:04 ET |
Barr Receives Approval For Generic Tambocor(TM) Heart Drug
|
|
Oct 24, 02
|
| 11:53 ET |
Election of Board of Directors of Barr Laboratories, Inc.
|
|
Oct 22, 02
|
| 08:52 ET |
Barr Receives Final FDA Approval for Two Oral Contraceptives; Company Will Launch Generic Versions of NOR-QD(R) and Ortho-Micronor(R)
|
|
Oct 17, 02
|
| 08:07 ET |
Barr Laboratories, Inc. Invites You to Join Its 2002 Annual Meeting of Shareholders on the Web
|
|
| 07:45 ET |
Barr Laboratories, Inc. Invites You to Join Its 2002 Annual Meeting of Shareholders on the Web
|
|
Sep 25, 02
|
| 12:55 ET |
Barr's Generic Ortho-Cyclen(R) Tablets Approved; Company to Market Oral Contraceptive Under Sprintec(TM) Trademark
|
|
Sep 23, 02
|
| 00:01 ET |
Barr to Challenge FDA Opinion that Delays Launch of Its Manufactured Tamoxifen 10 mg Tablet
|
|
Sep 17, 02
|
| 13:00 ET |
Barr's SEASONALE(R) NDA Accepted for Filing by FDA
|
|
Sep 04, 02
|
| 09:32 ET |
Barr's Nortel(TM) 7/7/7 Oral Contraceptive Receives Final Approval; Company Plans to Launch Generic Product in January 2003, Nine Months Prior To Patent Expiry
|
|
Aug 29, 02
|
| 09:18 ET |
District Court Denies Shire's Motion for Preliminary Injunction in Adderall(R) Trade Dress Infringement Suit
|
|
Aug 19, 02
|
| 11:54 ET |
Barr Challenging Patents Protecting Niaspan(R) 500 and 750 mg Extended Release Tablets
|
|
Aug 14, 02
|
| 08:10 ET |
Barr Reports Fiscal 2002 Earnings of $4.63 Per Share and Fourth Quarter Earnings of $0.98 Per Share Earnings for the Year Reflect Merger Charges and Other Items
|
|
| 08:00 ET |
Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast
|
|
| 08:00 ET |
Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast
|
|
Aug 07, 02
|
| 08:03 ET |
Webcast Alert: Barr Laboratories, Inc. Announces Fourth Quarter/Fiscal 2002 Year End Webcast
|
|
Aug 02, 02
|
| 17:32 ET |
Barr Labs Announces Fourth Quarter/Fiscal 2002 Year End Earnings Release Date and Conference Call
|
|
Jun 28, 02
|
| 09:49 ET |
Barr Launches Two Additional Generic Oral Contraceptive Products
|
|
Jun 21, 02
|
| 13:36 ET |
Barr's Cenestin(R) 0.3 Mg Tablets Approved Broadens Cenestin Product Franchise to Four Strengths
|
|
Jun 12, 02
|
| 13:05 ET |
Barr Receives Approval for Lithium Carbonate Extended-Release Tablets 300 mg
|
|
Jun 06, 02
|
| 10:53 ET |
Barr Completes Asset Purchase of Enhance Pharmaceuticals
|
|
Jun 03, 02
|
| 08:27 ET |
Barr Elects Governor James S. Gilmore, III, to Board of Directors
|
|
May 24, 02
|
| 09:10 ET |
Barr's Generic Nordette(R) Tablets Approved
|
|
May 22, 02
|
| 09:10 ET |
Barr Says Arington Resigns from Board of Directors; Former Duramed Chief to Pursue Other Business Ventures
|
|
May 08, 02
|
| 08:04 ET |
Barr Third Quarter 2002 EPS Climbs to $1.17; Revenues Increase 64% to $261.4 Million in Quarter
|
|
| 08:00 ET |
Webcast Alert: Barr Laboratories, Inc. Announces Its Third Quarter Fiscal 2002 Earnings Conference Call on the Web; Live and Archived Conference Call Notification
|
|
May 07, 02
|
| 11:08 ET |
Barr Challenging Patents Protecting Remeron(R) SolTab(TM)
|
|
May 06, 02
|
| 10:00 ET |
Barr's SEASONALE(TM) Oral Contraceptive Phase III Clinical Trial Results Subject of ACOG Poster Session
|
|
May 03, 02
|
| 09:15 ET |
Barr Terms Shire's Adderall Trade Dress Infringement Suit Without Merit; Calls Court Action Last Attempt to Sabotage Consumer Savings
|
|
May 02, 02
|
| 08:00 ET |
Webcast Alert: Barr Laboratories, Inc. Announces Its Third Quarter Fiscal 2002 Earnings Conference Call on the Web; Live and Archived Conference Call Notification
|
|
Apr 30, 02
|
| 09:54 ET |
Barr, Bristol-Myers Restructure Former DuPont Product Development And Marketing Agreements
|
|
Apr 29, 02
|
| 09:25 ET |
Barr Labs Announces Third Quarter Fiscal 2002 Earnings Release Date and Conference Call
|
|
Apr 24, 02
|
| 13:04 ET |
Barr's Generic Fosamax(R) 70 mg Tablet and 35 mg Tablet Products Tentatively Approved by FDA
|
|
Apr 23, 02
|
| 11:28 ET |
Barr Launches Lessina(TM) Oral Contraceptive Tablets; Generic Levlite(TM) Tablets Marketed as Branded Generic
|
|
Apr 08, 02
|
| 08:37 ET |
Barr Receives Final Approval for Generic Mircette(R) Oral Contraceptive Company Will Launch Product Immediately Under Kariva(TM) Trademark
|
|
Mar 21, 02
|
| 16:00 ET |
Barr Signs Asset Purchase Agreement with Enhance Pharmaceuticals, Inc.; $44 million Cash Purchase Would Give Company Novel Vaginal Drug Delivery Technology, Several NDA Products in Various Stages of Development
|
|
| 08:05 ET |
Barr's Generic Levlite(TM) Tablets Approved
|
|
Mar 06, 02
|
| 10:44 ET |
Barr Signs Agreements With Natural Biologics, LLC to Develop 'AB' Rated Conjugated Estrogens
|
|
Mar 05, 02
|
| 09:33 ET |
Barr Challenging Patents Protecting Niaspan(R) 1000 mg Extended-Release Tablet
|
|
Feb 28, 02
|
| 10:47 ET |
Barr Names Frederick J. Killion Senior Vice President & General Counsel Brings 20 Years of Experience to General Counsel Position
|
|
Feb 11, 02
|
| 15:46 ET |
Barr Receives Approval for Generic Adderall(R) Tablets
|
|
Feb 04, 02
|
| 09:04 ET |
Barr Receives Approval for Generic Prozac(R) 10 mg Tablets Company Will Launch Immediately
|
|
Jan 31, 02
|
| 15:17 ET |
Barr Receives Approval for Generic Prozac(R) 10 mg Capsules; Company Will Launch Immediately
|
|
Jan 30, 02
|
| 10:49 ET |
Barr Challenging Patents Protecting ALLEGRA-D(R); Company Also Challenging Allegra Capsule and Tablet Patents
|
|
Jan 29, 02
|
| 07:36 ET |
Barr Reports Second Quarter 2002 EPS of $0.91 Excluding Merger Related Charges and Other Non-Recurring Items EPS Was $1.40
|
|
Jan 25, 02
|
| 17:26 ET |
Barr Receives Approval for Generic Glucophage(R) Tablets; Company Will Launch Generic Glucophage Immediately
|
|
Jan 22, 02
|
| 12:17 ET |
Barr Receives Approval for Generic Dexedrine(R) Spansule(R) Capsules; Company Will Launch First Generic Dexedrine Spansule Product
|
|
| 10:01 ET |
Barr Announces Second Quarter Fiscal 2002 Earnings Release Date and Conference Call
|
|
Jan 14, 02
|
| 11:03 ET |
Supreme Court Denies Cert Petition in Prozac Patent Challenge
|
|
Jan 09, 02
|
| 09:20 ET |
Barr Confirms Prozac Exclusivity Runs Until January 29
|
|
Dec 18, 01
|
| 09:03 ET |
Barr Receives Letter Closing Ciprofloxacin Settlement Review by States; Texas, on Behalf of Several States, Ends Investigation
|
|
Dec 17, 01
|
| 11:18 ET |
Barr Initiates Patent Challenge of Fosamax(R) 35 mg Tablet Product; Company Also Challenging Patents Protecting 70 mg Tablet
|
|
Dec 12, 01
|
| 10:53 ET |
Barr Challenging Patent Protecting FemHrt(R) Tablets
|
|
Dec 11, 01
|
| 09:50 ET |
Barr's Warfarin Now Substitutable in Florida Rule Modernizing Negative Formulary Takes Effect
|
|
Dec 07, 01
|
| 08:55 ET |
Barr Granted Summary Judgment in Mircette Patent Challenge
|
|
Dec 06, 01
|
| 09:58 ET |
Barr Management Unveils Female Healthcare Franchise Opportunities; Reiterates Commitment to $4 per Share in Earnings in Fiscal 2003 to Analysts
|
|
Dec 04, 01
|
| 12:15 ET |
Barr's Generic LO/OVRAL Oral Contraceptive Approved; Seventh Generic OC in Company's Portfolio
|
|
| 09:01 ET |
Barr to Webcast Analyst Briefing on December 6, 2001
|
|
Dec 03, 01
|
| 17:11 ET |
Barr to Webcast Analyst Briefing on December 6, 2001
|
|
| 09:03 ET |
Barr Receives Tentative Approval for Mircette Oral Contraceptive
|
|
Nov 28, 01
|
| 09:51 ET |
Barr Awaiting Approval for Generic Adderall(R) Tablets Begins Soliciting Customer Orders to Manage Anticipated Demand
|
|
Nov 27, 01
|
| 10:39 ET |
Barr Receives Approval for Generic Myambutol(R) Tablets
|
|
Nov 20, 01
|
| 09:43 ET |
Barr to Webcast Analyst Briefing on December 6, 2001
|
|
Nov 14, 01
|
| 15:14 ET |
Barr Expects Increase in Second Quarter EPS; Provides Estimate Including Duramed Operations
|
|
Oct 29, 01
|
| 12:12 ET |
Barr Laboratories Announces Agreement in Ortho-Novum 7/7/7(R) Patent Litigation
|
|
Oct 25, 01
|
| 12:42 ET |
Election of Board of Directors of Barr Laboratories, Inc.
|
|
Oct 24, 01
|
| 16:18 ET |
Barr Announces Completion of Merger With Duramed; Merger Accelerates Drive to Leadership in Female Healthcare
|
|
Oct 23, 01
|
| 09:45 ET |
Barr Laboratories, Inc. Invites You to Join Its First Quarter Conference Call NEW CALL IN NUMBER LISTED BELOW
|
|
| 08:09 ET |
Barr Reports First Quarter 2002 EPS of $1.80
|
|
Oct 22, 01
|
| 08:39 ET |
Barr Laboratories, Inc. Invites You to Join Its First Quarter Fiscal 2002 Conference Call on the Web
|
|
Oct 18, 01
|
| 08:37 ET |
Barr Laboratories, Inc. Invites You to Join Its First Quarter Fiscal 2002 Conference Call on the Web
|
|
Oct 04, 01
|
| 06:45 ET |
Barr Increases First Quarter Earnings Estimates
|
|
Oct 01, 01
|
| 09:37 ET |
Barr Stock Repurchase Program Authorization Continued
|
|
Sep 28, 01
|
| 10:42 ET |
Barr Awarded $35 Million DOD Contract to Develop Adenovirus Vaccines
|
|
Sep 24, 01
|
| 08:38 ET |
Barr Extends Repurchase Program Following Extension of SEC Emergency Order
|
|
Sep 21, 01
|
| 08:19 ET |
Barr/Duramed Hart-Scott-Rodino Waiting Period Expires; Companies Set October Shareholder Meetings to Complete Merger
|
|
Sep 18, 01
|
| 15:06 ET |
Barr Receives Approval for Generic Eulexin(R) Tablets
|
|
Sep 17, 01
|
| 08:48 ET |
Barr Prepared to Repurchase Common Stock Under SEC Emergency Order; Board of Directors Authorizes Buy Back of Shares Up to Value of $100 Million
|
|
Sep 05, 01
|
| 11:47 ET |
Barr Initiates Patent Challenge of Fosamax(R)
|
|
Sep 04, 01
|
| 12:39 ET |
Barr's Generic Prozac 10 mg Tablet Tentatively Approved by FDA; Company Expands Prozac Product Line With Tablet Product
|
|
Aug 09, 01
|
| 15:54 ET |
Barr Challenging Patents Protecting Estrostep Fe
|
|
Aug 07, 01
|
| 08:06 ET |
Barr Fourth Quarter EPS Climbs to $0.49 Including $0.04 Per Share Special Charge
|
|
Aug 06, 01
|
| 12:14 ET |
Barr Initiates Challenge to Allegra(R) 60 mg Capsule Patents
|
|
| 10:00 ET |
Barr Laboratories, Inc. Invites You to Join Its Fourth Quarter/Fiscal 2001 Year End Conference Call on the Web
|
|
Aug 02, 01
|
| 16:16 ET |
Barr Laboratories Ships Generic Prozac
|
 |
| 14:01 ET |
Barr Laboratories Ships Generic Prozac
|
|
Aug 01, 01
|
| 10:01 ET |
Barr Laboratories, Inc. Invites You to Join Its Fourth Quarter/Fiscal 2001 Year End Conference Call on the Web
|
|
Jul 30, 01
|
| 13:38 ET |
Barr's Chairman and CEO to Appear on Bloomberg Television
|
|
| 11:19 ET |
Indiana District Court Clears Way for Barr's Generic Prozac(R) Launch
|
|
Jul 18, 01
|
| 15:26 ET |
Barr Schedules Conference Call Regarding Prozac Decision
|
|
| 14:42 ET |
Court of Appeals Denies Re-hearing in Prozac(R) Patent Challenge; Court Decision Paves Way for Barr's Generic Launch
|
|
Jul 11, 01
|
| 07:32 ET |
Barr Increases Fourth Quarter Earnings Estimates
|
|
Jul 03, 01
|
| 11:54 ET |
Barr Intends to Seek Approval of Generic Allegra
|
|
Jun 29, 01
|
| 10:22 ET |
Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc. Fact Sheet
|
|
| 10:22 ET |
Barr to Conduct Conference Call on Merger Agreement With Duramed Pharmaceuticals, Inc.
|
|
| 10:21 ET |
Barr and Duramed Announce Merger Agreement
|
|
Jun 01, 01
|
| 12:06 ET |
Barr Says Florida Governor's Signature Will Save Consumers Millions
|
|
May 30, 01
|
| 19:03 ET |
Barr Victorious in Challenge of Prozac Patent; U.S. Court of Appeals Panel Reaffirms Decision Invalidating Prozac Patent
|
|
| 18:40 ET |
Barr to Conduct Conference Call on Prozac(R) Ruling on May 31, 2001
|
|
| 16:36 ET |
Barr Victorious in Challenge of Prozac Patent; U.S. Court of Appeals Panel Reaffirms Decision Invalidating Prozac Patent
|
|
| 11:24 ET |
Barr Receives Approval for Generic Aygestin(R) Tablets
|
|
May 29, 01
|
| 12:37 ET |
Barr Launches Generic Ortho-Novum(R) 1/35 and Modicon(R)-28 Tablets
|
|
May 17, 01
|
| 13:34 ET |
Barr Confirms Receipt of Massachusetts Subpoena
|
|
May 10, 01
|
| 08:55 ET |
Barr Reports Third Quarter EPS Climbs to $0.45; Includes $0.03 Per Share Gain on Sale of Securities
|
|
May 09, 01
|
| 16:17 ET |
Barr Says Tamoxifen Patent Settlement is Pro-Consumer and Pro-Competitive
|
|
| 07:31 ET |
Barr Laboratories, Inc. Invites You to Join Its Third Quarter Conference Call on the Web
|
|
May 07, 01
|
| 12:40 ET |
Barr Laboratories, Inc. Invites You to Join Its Third Quarter Conference Call on the Web
|
|
May 04, 01
|
| 09:10 ET |
Barr Files Amendment to Stock Offering; Company Anticipates Secondary Stock Offering in May
|
|
May 02, 01
|
| 11:39 ET |
Barr Says Florida Senate Approval of Generic Bill Will Save Consumers $15-20 Million Annually
|
|
Apr 02, 01
|
| 12:03 ET |
Barr Says Ciprofloxacin Patent Challenge Creates Significant Consumer Benefit; Says Wall St. Journal Story Contains No New Information
|
|
| 08:44 ET |
Barr Announces 4 Year Contract Agreement with PACE
|
|
Mar 28, 01
|
| 08:46 ET |
Barr Expects No Disruption of Supply to Customers in Event of NY/NJ Strike
|
|
Mar 22, 01
|
| 12:09 ET |
Barr's Proprietary Methotrexate Product Approved by FDA Company Will Market New Dosage Strengths Under Trexall TM Trademark
|
|
Mar 13, 01
|
| 14:57 ET |
Barr's Generic Ortho-Novum(R) 1/35 and Modicon(R)-28 Tablets Approved; Company Plans to Market Both Oral Contraceptives Under Nortrel(TM) Trademark
|
|
Mar 12, 01
|
| 12:15 ET |
Barr's Generic Ortho-Novum 7/7/7 Tentatively Approved by FDA
|
|
Mar 09, 01
|
| 11:01 ET |
Barr Disputes Position of FDA on Generic Exclusivity, Pediatric Exclusivity
|
|
Feb 12, 01
|
| 10:05 ET |
Barr Names Dr. Carole Ben-Maimon, Harold N. Chefitz to Board of Directors
|
|
Feb 08, 01
|
| 09:01 ET |
Barr Reports Second Quarter EPS of $0.44 Including $0.07 Per Share Gain on Sale of Securities
|
|
Feb 06, 01
|
| 13:44 ET |
Barr Laboratories, Inc. Invites You to Join Its Second Quarter Conference Call on the Web
|
|
Feb 01, 01
|
| 09:22 ET |
Barr Receives Approval for Generic Dextrostat(R) Tablets
|
|
Jan 29, 01
|
| 09:00 ET |
Barr Receives Approval for Generic Cordarone(R) Tablets
|
|
Jan 26, 01
|
| 08:30 ET |
Barr Receives Approval for Generic LUVOX(R) Tablets
|
|
Jan 25, 01
|
| 09:32 ET |
Barr Names MGI PHARMA, INC. to Market MYLOCEL(TM) Tablets
|
|
Jan 16, 01
|
| 10:33 ET |
Barr Names Charlene Good Polino Vice President, Strategic Business Development
|
|
Jan 08, 01
|
| 13:18 ET |
Barr Names Dr. Carole S. Ben-Maimon President and COO of Proprietary Research And Development New Business Unit Will Focus on Proprietary Products
|
|
Oct 26, 00
|
| 11:14 ET |
Barr's Downey Emphasizes Record Commitment to New Product Development
|
|
| 07:45 ET |
Barr Laboratories, Inc. Invites You to Join Its 2000 Annual Meeting of Shareholders on the Web
|
|
Oct 24, 00
|
| 16:31 ET |
Barr Laboratories, Inc. Invites You to Join Its 2000 Annual Meeting of Shareholders on the Web
|
|
| 09:09 ET |
Barr Reports First Quarter 2001 EPS of $0.38 Before Special Charges
|
|
| 08:13 ET |
Barr Laboratories, Inc. Invites You to Join Its First Quarter Fiscal 2001 Conference Call on the Web
|
|
Oct 03, 00
|
| 09:25 ET |
Barr Receives Approval for Generic TYLOX(R) Tablets
|
|
Sep 25, 00
|
| 11:56 ET |
Barr Receives Approval for Proprietary Hydroxyurea Capsules 250 mg; New Dosage Strength Completes Hydroxyurea Proprietary Product Line
|
|
Sep 14, 00
|
| 17:49 ET |
Barr Laboratories Files Registration Statement for Common Stock Offering Sale of 3.5 Million Shares Anticipated to Increase Liquidity
|
|
Sep 11, 00
|
| 14:47 ET |
Barr Says Recruitment Ongoing for Proprietary Drug Trials Says R&D Activity in Fiscal 2001 Remains High
|
|
Aug 30, 00
|
| 13:01 ET |
Barr Receives Approval for Proprietary Hydroxyurea Tablets 1000mg
|
|
Aug 29, 00
|
| 11:52 ET |
Barr Initiates Challenge of Raw Material Patents on Tambocor(TM) Heart Drug
|
|
Aug 09, 00
|
| 19:05 ET |
UPDATE: Barr to Conduct Conference Call Regarding Prozac Ruling On August 10, 2000
|
|
| 15:40 ET |
Barr to Conduct Conference Call Regarding Prozac Ruling
|
|
| 14:47 ET |
Prozac(R) Patent Ruled Invalid by U.S. Court of Appeals
|
|
Aug 08, 00
|
| 08:45 ET |
Barr Reports 20% Increase in Fourth Quarter Net Earnings - Product Development Investment Reaches Record $40 Million in Fiscal 2000 -
|
|
Aug 07, 00
|
| 09:02 ET |
Barr Laboratories, Inc. Invites You to Join Its Fourth Quarter/Fiscal Year End Conference Call on the Web
|
|
Aug 04, 00
|
| 09:01 ET |
Barr Laboratories, Inc. Invites You to Join Its Fourth Quarter/Fiscal Year End Conference Call on the Web
|
|
Jun 29, 00
|
| 08:32 ET |
Barr Laboratories Announces Stock Split Distribution
|
|
Jun 13, 00
|
| 09:04 ET |
Barr Initiates Challenge of Patent Protecting Ortho Tri-Cyclen Oral Contraceptive
|
|
May 31, 00
|
| 13:48 ET |
Barr Laboratories Challenging Patents on Prozac(R) 10mg Tablets
|
|
| 09:32 ET |
Barr Laboratories Announces 3 for 2 Stock Split; Shareholders to Benefit from Increased Liquidity
|
|
May 26, 00
|
| 09:07 ET |
Barr Launches 'warfarininfo.com' Web Site; Leading Supplier of Generic Anticoagulant Creates New Information Resource
|
|
May 23, 00
|
| 13:45 ET |
Barr Files IND for SEASONALE(TM) Oral Contraceptive
|
|
May 19, 00
|
| 09:42 ET |
Barr Says Warfarin Federal Upper Limits (FUL) Listing Will Promote Generic Usage
|
|
May 10, 00
|
| 15:12 ET |
Generic Pharmaceutical Industry Associations to Unify
|
|
Apr 20, 00
|
| 09:17 ET |
Barr Reports Third Quarter EPS of $0.61 Before One-time Charges; $7.2 Million In Revenue from DuPont R&D and Co-marketing Venture
|
|
| 08:00 ET |
Barr Laboratories, Inc. Invites You to Join Its Third Quarter Conference Call on the Web
|
|
Apr 17, 00
|
| 14:15 ET |
Barr Laboratories, Inc. Invites You to Join Its Third Quarter Conference Call on the Web
|
|
Mar 21, 00
|
| 08:31 ET |
Barr Laboratories & DuPont Pharmaceuticals Sign Definitive Agreements for Development and Marketing Venture
|
|
Feb 23, 00
|
| 13:10 ET |
Prozac Patent Challenge Appeals Court Hearing Set for March 8; Court Agrees to Open Hearing on Double Patenting and Best Mode Claims
|
|
Feb 15, 00
|
| 17:35 ET |
Texas Board of Pharmacy Rejects Limits on Generic Substitution; Unanimous Decision Ensures Continued Savings for Consumers
|
|
Feb 08, 00
|
| 09:30 ET |
Barr Says Patient Recruitment for CyPat(TM) Prostate Drug Clinical Trials Underway
|
|
Jan 20, 00
|
| 09:00 ET |
Barr Laboratories, Inc. Invites You to Join Its Second Quarter Conference Call on the Web
|
|
| 08:35 ET |
Barr Reports Second Quarter EPS of $0.53; Commitment to Product Development Results in 76% Increase in R&D Spending
|
|
| 08:32 ET |
Barr Laboratories & DuPont Pharmaceuticals to Form Strategic Relationship
|
|
Jan 18, 00
|
| 08:30 ET |
Barr Laboratories, Inc. Invites You to Join Its Second Quarter Conference Call on the Web
|
|
Dec 01, 99
|
| 12:07 ET |
Barr Praises FDA Column in JAMA Confirming Safety, Efficacy of Generic Drugs Calls on Brand Industry to End Anti-Generic Substitution Initiatives
|
|
| 09:31 ET |
Barr Names Martin Zeiger Senior Vice President, Strategic Business Development & General Counsel
|
|
Nov 10, 99
|
| 08:04 ET |
Texas Pharmacy Board Unamimously Rejects Restrictions on Generic Substitution
|
|
Nov 03, 99
|
| 13:33 ET |
Barr Says Florida Legislative Vote Sets Stage to Increase Access to Generics; Senate Health Committee Formalizes Recommendations of Pro-Generic Study
|
|
Oct 28, 99
|
| 10:18 ET |
Barr Names Mary E. Petit Senior VP, Proprietary Product Development
|
|
| 10:16 ET |
Barr Names Jake Hansen Vice President of Government Affairs
|
|
| 10:13 ET |
Barr's Downey Tells Shareholders Growth Potential Built on Sound Foundation; Announces Appointment of New President, Aligns Management Team to Deliver Results
|
|
| 10:11 ET |
Barr Names Paul M. Bisaro President and Chief Operating Officer
|
|
Oct 25, 99
|
| 12:13 ET |
Barr Announces Annual Meeting of Shareholders Fifth Consecutive Year of Record Revenue and Earnings Growth Detailed
|
|
Oct 21, 99
|
| 08:59 ET |
Barr Reports First Quarter 2000 EPS of $0.49 Per Share; Quarter Includes Revenue Gain, Higher Margins, $9 Million Investment in R&D
|
|
Oct 05, 99
|
| 09:24 ET |
Barr Launches 'tamoxifencitrate.com' Web Site, Risk Assessment Toll Free Number
|
|
Sep 30, 99
|
| 11:28 ET |
Barr Encouraged by USA Today Story Regarding Tamoxifen Agreement
|
|
Sep 13, 99
|
| 10:00 ET |
Barr to Initiate Clinical Studies for Two Proprietary Drugs; Broad Advances in Proprietary Development Headline Expanded R&D Program
|
|
Sep 09, 99
|
| 10:52 ET |
Barr Urges Florida Lawmakers to Support Elimination of Negative Formulary Senate Committee Interim Report Confirms Substitutability of Generic Drugs
|
|
Aug 11, 99
|
| 18:27 ET |
Barr Applauds Texas Pharmacy Board Decision Rejecting Restrictions on Generic Substitution
|
|
Aug 10, 99
|
| 09:19 ET |
Barr EPS Jumps 48% to $2.09 for Fiscal 1999; Earnings Exceed Consensus, Result from Double-Digit Revenue Growth
|
|
Aug 05, 99
|
| 09:08 ET |
Barr Dedicates NY Warehouse, Announces $3 Million Laboratory Expansion
|
|
Aug 03, 99
|
| 08:31 ET |
Barr Urges Illinois Legislature to Override Governor's Veto of HB 2256; Legislature Can Act to Save Consumers Millions on Generic Medicines
|
|
Jul 19, 99
|
| 17:04 ET |
Barr Calls EVISTA Injunction Victory for Breast Cancer Patients; Judge Says Lilly EVISTA Claims 'Literally False'
|
|
Jun 28, 99
|
| 09:42 ET |
Barr Says Tamoxifen Patent Settlement is Pro-Consumer and Pro-Competitive Challenges Conclusions of 'USA Today' Story
|
|
Jun 23, 99
|
| 13:24 ET |
Barr Receives FDA Approval for Cefadroxil 500 mg Capsules; Announces Co-marketing Agreement for Cefadroxil 1 gram Tablets
|
|
Jun 03, 99
|
| 11:06 ET |
Barr Praises Position of 'The Medical Letter' on Generic Warfarin Sodium Tablets
|
|
May 25, 99
|
| 11:39 ET |
Barr Outlines Strategy for Growth Through 2003; Proprietary, Generic and Patent Challenge Strategies will Fuel Growth
|
|
May 24, 99
|
| 08:52 ET |
Barr Named To Business Week Top 100 Hot Growth Companies; One of Only Three Pharmaceuticals Companies Named to List
|
|
May 14, 99
|
| 09:25 ET |
Barr Announces Additional Analyst Coverage; CIBC Oppenheimer Becomes Second Firm to Initiate Coverage in Quarter
|
|
Apr 30, 99
|
| 09:06 ET |
Barr Launches Trazodone 150 mg and 300 mg Tablets; Only Company to Market All Four Trazodone Strengths
|
|
Apr 21, 99
|
| 08:39 ET |
Barr's Third Quarter Earnings Climb 74% to $0.54 Per Share
|
|
Mar 29, 99
|
| 10:29 ET |
Barr Seeks to Intervene in Zeneca Inc.'s EVISTA Suit
|
|
Mar 09, 99
|
| 09:21 ET |
FDA Affirms Barr's 180 Day Generic Tamoxifen Exclusivity
|
|
Mar 03, 99
|
| 10:30 ET |
Barr Claims Victory for Indiana Consumers
|
|
Feb 25, 99
|
| 08:51 ET |
Illinois Approves Barr's Generic Coumadin for Substitution
|
|
Feb 23, 99
|
| 10:23 ET |
Barr Wins Another Pre-Trial Victory in DuPont Anti-Trust Suit
|
|
Feb 10, 99
|
| 09:37 ET |
Barr Named Wal-Mart's Pharmaceutical Vendor of the Year
|
|
Feb 09, 99
|
| 18:26 ET |
Barr Pledges to Continue Fight for Consumers in Texas
|
|
Feb 08, 99
|
| 10:31 ET |
Barr Initiates Challenge of Ortho-Novum 7/7/7 Patents; $160 Million Oral Contraceptive Complements Female Healthcare Franchise
|
|
Feb 02, 99
|
| 14:46 ET |
Barr Charges DuPont with 'Poisoning' Climate for Generics in Florida; Elects to Temporarily Withdraw Warfarin Application from Negative Formulary
|
|
Feb 01, 99
|
| 10:36 ET |
Barr Acquires Rights to New Proprietary Oral Contraceptive; Product Represents Collaboration with Eastern Virginia Medical School
|
|
Jan 25, 99
|
| 08:55 ET |
Barr to Take Prozac Challenge Directly to Court of Appeals Defendants Agree to Drop Inequitable Conduct and Anticipation Claims
|
|
Jan 21, 99
|
| 09:29 ET |
Barr Laboratories' Second Quarter EPS Increases 93% to $0.52; 68% Increase in Sales of Manufactured Products Drives Impressive Performance
|
|
Jan 13, 99
|
| 10:14 ET |
Barr Prozac Challenge to Proceed on Grounds of Inequitable Conduct; Company Disappointed with Judge's Decision Dismissing Additional Claims
|
|
Dec 31, 98
|
| 17:00 ET |
Barr Says Tamoxifen Patent Settlement Has Resulted in Significant Consumer Savings
|
|
Dec 17, 98
|
| 08:58 ET |
Texas Judge Strikes Down Board of Pharmacy Anti-substitution Rule as Invalid; Barr Laboratories Successful in Court Challenge of DuPont Sponsored Restriction
|
|
Dec 14, 98
|
| 12:00 ET |
Barr's Warfarin Approved by Department of Defense Committee Brand Designation Removed Allowing Substitution
|
|
Dec 09, 98
|
| 11:00 ET |
Barr Announces Construction of New York Warehouse $3 Million Project Brings NY Investment to $12 Million Since 1996
|
|
| 11:00 ET |
Barr's Downey Highlights Proprietary Pipeline During Annual Meeting CEO Describes Progress in Company's Three-Tier Business Strategy
|
|
Dec 08, 98
|
| 17:47 ET |
Delaware Judge Rejects DuPont Motion to Dismiss Barr's Anti-Trust Case
|
|
| 13:33 ET |
Virginia Board of Pharmacy Rejects DuPont Effort to Limit Warfarin Substitution; Barr Hails Decision as Scientifically Based
|
|
Nov 23, 98
|
| 10:55 ET |
Minnesota Rejects DuPont's Anti-Substitution Initiative for Second Time Formulary Committee Reaffirms Decision to Remove Warfarin from Negative Formulary
|
|
Nov 10, 98
|
| 08:53 ET |
Barr Expands Warfarin Sodium Product Line FDA Approves Generic 3mg and 6 mg Tablet Strengths of Coumadin(R)
|
|
Nov 09, 98
|
| 12:26 ET |
Second Published Clinical Study Confirms Substitutability of Barr's Warfarin
|
|
Nov 02, 98
|
| 11:43 ET |
Barr Names Michael Moorshead V.P. of Manufacturing and Engineering
|
|
Oct 29, 98
|
| 16:02 ET |
Barr Praises FDA's Approval of Tamoxifen for Women-at-Risk of Breast Cancer
|
|
Oct 22, 98
|
| 08:45 ET |
Barr Laboratories' First Quarter 1999 EPS Increases to $0.48; Products Launched in Past 12 Months Drive Earnings Increase
|
|
Oct 21, 98
|
| 12:44 ET |
Barr Corrects Factual Errors in Bear Stearns Report
|
|
Oct 19, 98
|
| 09:40 ET |
Barr Launches Generic Hydrea Cancer Treatment
|
|
Oct 14, 98
|
| 14:02 ET |
Barr Charges DuPont with Misleading Public About Generic Warfarin Substitution
|
|
Sep 28, 98
|
| 12:44 ET |
Barr Laboratories and Gynetics, Inc. to Collaborate on Oral Contraceptive NDA Product
|
|
Sep 15, 98
|
| 18:46 ET |
Barr Praises Court Decision Preventing Restrictions on Generics; Travis County Court Acts in Favor of Consumers and Affordable Medicine
|
|
Sep 02, 98
|
| 11:48 ET |
Barr's First Proprietary Product Receives FDA Approval; Contraceptive Product Co-Developed with Gynetics, Inc.
|
|
Aug 20, 98
|
| 08:40 ET |
Barr Laboratories Reports Record Fiscal 1998 EPS of $1.45 Revenues Climb to $377 Million; Net Earnings Jump to $32.7 Million
|
|
Aug 12, 98
|
| 11:04 ET |
Group Health Cooperative of Puget Sound Places Barr Laboratories' Warfarin Sodium on Its Drug Program Formulary
|
|
Aug 10, 98
|
| 11:02 ET |
Barr's Warfarin Approved for Minnesota Medicaid Patients; Formulary Committee Removes Generic Anti-Coagulant, Other Drugs from Negative Formulary
|
|
Jul 29, 98
|
| 12:10 ET |
Barr's Warfarin Sodium Tablets Added to Kaiser Permanente's Drug Program Formulary
|
|
Jun 30, 98
|
| 09:24 ET |
Barr Launches Generic Danazol 50 mg and 100 mg Capsules
|
|
Jun 29, 98
|
| 09:47 ET |
Paul M. Bisaro Elected to Barr Laboratories' Board of Directors
|
|
May 19, 98
|
| 09:33 ET |
Barr Receives Approval for Generic Maxide(R)-25mg Tablets
|
|
May 08, 98
|
| 12:35 ET |
Barr Receives First Approval for Generic Revia(R) Tablets; Used in Treatment of Alcohol Dependence and to Block Effects of Opioids
|
|
Apr 30, 98
|
| 08:20 ET |
Barr Laboratories Reports $0.31 Third Quarter EPS; Total Revenues of $96 Million Climb 14% on Increase in Net Product Sales of 46%
|
|
Mar 17, 98
|
| 10:06 ET |
Barr Laboratories Completes Common Stock Offering
|
|
Mar 09, 98
|
| 09:57 ET |
Barr Files Anti-Trust Suit Against DuPont Merck; DuPont Merck's Actions Show Consistent Pattern of Anti-Competitive Behavior
|
|
Feb 25, 98
|
| 14:50 ET |
Barr Says Suit Filed by Invamed is Without Merit
|
|
Feb 10, 98
|
| 11:27 ET |
Barr Laboratories Begins Trading on New York Stock Exchange
|
|
Feb 03, 98
|
| 10:50 ET |
Clinical Study Offers New Option to Patients Who Need Life-Saving Drug; Generic Warfarin Sodium Can Save Americans, Consumers and Taxpayers Millions
|
|
Feb 02, 98
|
| 09:16 ET |
Barr Laboratories Files Registration Statement for Common Stock Offering
|
|
Jan 29, 98
|
| 09:20 ET |
Barr Laboratories Applies for Listing on New York Stock Exchange
|
|
Jan 22, 98
|
| 09:57 ET |
Barr Laboratories Reports Second Quarter EPS of $0.31 vs. $0.10 Last Year; Revenues Increase 37% to $92 Million; Net Earnings Climb 184% to $6 Million
|
|
Jan 07, 98
|
| 09:30 ET |
Barr Receives Approval for Generic Dyazide(R) Capsules
|
|
Dec 09, 97
|
| 12:53 ET |
NJ Drug Utilization Review Council Approves Barr's Generic Coumadin; Decision Provides NJ Consumers with Access to More Affordable Medicine
|
|
Dec 03, 97
|
| 11:00 ET |
Barr's Downey Cites Debt Refinancing, Growth in Warfarin Sodium Market Share, Virginia Facility Approvals Among Company Highlights at 1997 Annual Meeting
|
|
Nov 19, 97
|
| 11:08 ET |
Massachusetts Rejects DuPont Merck Petition to Block Barr's Generic Coumadin; Science Triumphs Over DuPont Merck's Anti-Consumer, Anti-Competitive Efforts
|
|
Nov 17, 97
|
| 10:06 ET |
Barr Says Clinical Trial Confirms Substitutability of Generic Coumadin; Study Dispels DuPont Merck's Patient Safety Claims
|
|
Oct 23, 97
|
| 09:35 ET |
Barr Laboratories Reports Record First Quarter EPS of $0.45; Revenues Increase 50% to $96 Million; Net Product Sales Climb 39%
|
|
Oct 22, 97
|
| 14:27 ET |
Barr Laboratories Adds Generic Estrace(R) to Hormonal Line; Third Product Launch in Fiscal 1998
|
|
Sep 26, 97
|
| 09:42 ET |
Barr Receives Approval for Generic Percocet(R) Tablets
|
|
Sep 11, 97
|
| 15:41 ET |
Barr Dedicates Manufacturing and Packaging/Warehouse Facility in Virginia
|
|
Sep 08, 97
|
| 10:33 ET |
Barr Laboratories to Market Warner Chilcott's Minocycline Anti-Microbial; First Product Resulting from Marketing/Manufacturing Corporate Collaboration
|
|
Aug 28, 97
|
| 09:35 ET |
Barr Laboratories Reports Record Fiscal 1997 EPS of $0.87; Revenues Climb to $284 Million; Net Earnings Jump to $19.4 Million
|
|
Aug 01, 97
|
| 17:10 ET |
Barr Responds to DuPont Merck Claims
|
|
Jul 28, 97
|
| 15:30 ET |
Facts About Barr's Warfarin Sodium (Generic Equivalent of Coumadin)
|
|
| 08:55 ET |
Barr Begins Shipments of Generic Version of Coumadin(R) Milestone in History of Barr, Generic Pharmaceutical Industry
|
|
| 08:53 ET |
Barr Launches Generic Version of Coumadin with Unprecedented Marketing Program
|
|
Jul 15, 97
|
| 12:31 ET |
Barr Laboratories Announces Equity Investment in Warner Chilcott
|
|
May 07, 97
|
| 15:51 ET |
Barr Laboratories Announces Stock Split Distribution
|
|
May 05, 97
|
| 14:22 ET |
Barr Laboratories Responds to FDA Decision on Conjugated Estrogen
|
|
Apr 14, 97
|
| 09:32 ET |
Barr Laboratories Announces $1.00 EPS for Third Quarter 1997; Board Authorizes 3-for-2 Stock Split in Recognition of Milestone Achievements
|
|
Mar 26, 97
|
| 16:04 ET |
FDA Approves Barr Laboratories' Generic Coumadin
|
|
Jan 28, 97
|
| 09:33 ET |
Barr Receives Approval for 50 mg Strength of Generic Demerol Tablets; Rounds Out Company's Meperidine Product Line
|
|
Jan 23, 97
|
| 09:31 ET |
Barr Laboratories Reports $0.15 EPS for Second Quarter 1997; Sales of $67 Million Represent 17% Increase
|
|
| 09:30 ET |
Barr Laboratories Reports $0.15 EPS for Second Quarter 1997; Sales of $67 Million Represent 17% Increase
|
|
Jan 17, 97
|
| 01:48 ET |
Barr Laboratories and Bayer AG Announce Agreement to Settle Patent Litigation
|
|
Dec 04, 96
|
| 11:15 ET |
Barr's Downey Cites Growth in Product Line, Infrastructure at 1996 Annual Meeting; CEO Also Announces Creation of New Product Development Team
|
|
| 11:13 ET |
Barr Launches Tamoxifen Citrate 20mg Tablets
|
|
Dec 02, 96
|
| 15:52 ET |
Barr Laboratories Expands Hormonal Line with Estropipate Approval; Represents Further Commitment to Be Category Leader
|
|
Nov 05, 96
|
| 13:07 ET |
Barr Responds to Wyeth-Ayerst Announcement Regarding PREMARIN; Company Says it Can Add Delta 8,9 if FDA Requires its Addition
|
|
Oct 28, 96
|
| 12:47 ET |
Barr Laboratories' Reports $0.12 Earnings Per Share For First Quarter 1997; Sales Climb 19% to $64 million
|
|
Oct 21, 96
|
| 09:32 ET |
Barr Laboratories Names Petit and Bisaro to Senior Vice President Posts; Promotes McKee to Chief Financial Officer
|
|
Oct 11, 96
|
| 10:36 ET |
Barr Laboratories Breaks Ground for Packaging Warehouse Facility in Virginia
|
|
Oct 08, 96
|
| 11:43 ET |
Barr Reintroduces Generic Demerol 100 mg Tablets; First Product in Company's Revitalized Pain Management Category
|
|
Oct 01, 96
|
| 12:17 ET |
Barr Laboratories Says Warfarin Sodium Product Approval is Pending
|
|
Sep 27, 96
|
| 13:26 ET |
Saving Consumers Millions is Focus of FDA, Generic Pharmaceutical Industry Meeting
|
|
Aug 29, 96
|
| 09:26 ET |
Barr Laboratories' Sales Climb 16% for Fiscal 1996; EPS Grows to $0.48 Record Revenues of $232 Million Reported
|
|
Aug 26, 96
|
| 09:28 ET |
Barr Launches 20 mg Megestrol Acetate Tablet; Rounds-Out Megestrol Solid Oral Dosage Line
|
|
Aug 13, 96
|
| 09:35 ET |
Barr Laboratories Launches Medroxyprogesterone Acetate; New Hormonal Agent Often Prescribed with Conjugated Estrogens
|
|
Aug 09, 96
|
| 12:41 ET |
FDA Approves Barr's Danazol; First New Product in Barr Laboratories' Hormonal Category
|
|
